Junctional Adhesion Molecule‐A ( JAM ‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70225 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Niamh McAuley und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Hauptthemen laut MEDLINE: Multiple Myeloma, Peptides, Cell Adhesion Molecules, Junctional Adhesion Molecule A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Research Charities Ireland (to A.M.H. and S.V.G.), Breakthrough Cancer Research, Health Research Board.
Abstract (Originalsprache)
Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM). Updated in 2025, the evolving cytogenetic classification of HR‐MM includes gains or amplifications in chromosome 1q. One gene of emerging interest on chromosome 1q is F11R, which codes for a protein called Junctional Adhesion Molecule‐A (JAM‐A). Upregulation of JAM‐A has been linked with the development of several aggressive malignancies, most recently MM. In the current study, F11R gene expression was found to be significantly higher in gain/amp(1q) MM patients from the CoMMpass database, and to correlate with poorer overall survival in MM patients. Furthermore, elevated F11R expression was accompanied by an increased burden of circulating CD138 + cells, potentially an early hallmark of extramedullary disease (EMD). As JAM‐A signalling putatively promotes tumorigenic behaviour through cis‐ dimerization‐dependent adhesion signalling, structure‐based rational design principles were utilised to design novel peptide inhibitors that selectively disrupt JAM‐A cis ‐dimerization. In vitro testing of novel peptides across a panel of MM cell lines and primary CD138+ cells from MM patients demonstrated anti‐proliferative and pro‐senescence properties of the novel peptides. Moreover, candidate peptide P4 significantly inhibited the growth of CD138+ plasmacytoma‐like tumours in an in vivo xenograft model involving implantation onto the chick chorioallantoic membrane. Collectively, these findings support the validity of JAM‐A as an emerging druggable target and provide a strong rationale for further preclinical investigations of JAM‐A inhibitors in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- Myeloma Research Group, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- Department of Pathology, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- Department of Haematology, Beaumont Hospital, Dublin, Ireland.
- Beaumont RCSI Cancer Centre, Dublin, Ireland.
ORCID-Profile: Ann M Hopkins
Förderung
- Health Research Charities Ireland (to A.M.H. and S.V.G.)
- Breakthrough Cancer Research
- Health Research Board
Zitieren
APA
McAuley, N., McAvera, R., Bong, D., Donnelly, L., Cymer, I., Brennan, M., Fay, J., Hudson, L., Quinn, J., Glavey, S. V., & Hopkins, A. M. (2026). Junctional Adhesion Molecule‐A ( JAM ‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo. European Journal of Haematology. https://doi.org/10.1111/ejh.70225
Vancouver
McAuley N, McAvera R, Bong D, Donnelly L, Cymer I, Brennan M, et al. Junctional Adhesion Molecule‐A ( JAM ‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo. European Journal of Haematology. 2026. doi:10.1111/ejh.70225
BibTeX
@article{McAuley2026,
author = {McAuley, Niamh and McAvera, Roisin and Bong, Dimitri and Donnelly, Lara and Cymer, Izabela and Brennan, Marian and Fay, Joanna and Hudson, Lance and Quinn, John and Glavey, Siobhan V and Hopkins, Ann M},
title = {Junctional Adhesion Molecule‐A ( JAM ‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70225}
}
EUVIMED